In WP1 “Precursor and Radiolabeling Methodology” we will use contemporary organic synthesis strategies for preparing facile radiolabeling substituents. This will include catalytic functionalization for 18F or 11C labeling, solid supported resin-bound methods and other late stage functionalization strategies. The strategies explored here will also be developed into methods for instrumental radiolabeling using current radiosynthesis modules and tools for routine high-activity production runs. Novel strategies for late-stage functionalization will be explored with the aim of synthesizing novel precursor molecules for fast and efficient radiolabeling. Novel radiolabeling methods based on the use of transition metals as the radionuclide will be pursued both for novel precursors as well as in comparison with established tracers. Regulatory aspects will also have to be considered here as methods should comply with e.g. European Pharmacopoeia requirements. This is important in order to make methods robust and increase availability.
The work proposed under this WP will be conducted in close collaboration with WP3.
Work package 1:
In WP1 “Precursor and Radiolabeling Methodology” we will use contemporary organic synthesis strategies for preparing facile radiolabeling substituents. This will include catalytic functionalization for 18F or 11C labeling, solid supported resin-bound methods and other late stage functionalization strategies. The strategies explored here will also be developed into methods for instrumental radiolabeling using current radiosynthesis modules…
Work package 2:
Radiolabeling with the promising radionuclide 45Ti and their immobilization on relevant peptides and development of peptide-chelator conjugates for immuno-PET imaging applications will be in focus. We are aiming to implement an efficient method for 45Ti isotope trapping via diol- functionalized resins, subsequently study the decomplexation of resin-bound 45Ti by wrapping the titanium with multidentate and…
Work package 3:
This work package will draw the current consortium wide expertise in kinase inhibitors (KIs) and jointly develop small molecule KIs for imaging and treatment of brain tumors. To achieve our goals we will utilize a dual strategy: Development of novel KIs radiolabeled with 11C and 18F and development of novel bioconjugates containing a therapeutic radiometal….
Work package 4:
Development of new tracers takes on average 13 years, similar to other pharmaceuticals. In order to increase patient care and precision diagnostics during the timeframe of this project, much attention will be given to WP4 “Tracer Implementation” to increase the number of locally available PET tracers. Due to the aforementioned costs associated with transport and…